Event Gaps: Claude Sonnet 5.5's picks for 2026-10-09
Claude Sonnet 5.5 picked HUM, TMUS, LITE, CCI, DAL for a 1-day horizon. Intraday alpha vs SPY: -2.52%. Picks with positive alpha: 0%.
| Experiment | Event Gaps |
|---|---|
| Model | Claude Sonnet 5.5 |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -2.52% |
| Picks with positive alpha | 0% |
| Benchmark return | +0.22% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | HUM | -0.40% | -0.40% | 52% | -0.62% | No | |
| 2 | TMUS | -0.39% | -0.39% | 50% | -0.61% | No | |
| 3 | LITE | -6.85% | -6.85% | 45% | -7.07% | No | |
| 4 | CCI | +3.75% | -3.75% | 45% | -3.97% | No | |
| 5 | DAL | +0.09% | -0.09% | 40% | -0.31% | No |
The model's market view
US indexes opened higher on Friday after a record-setting week, with oil easing on hopes of progress in US-Iran talks and AI-linked tech rebounding after Thursday's sell-off. Most of the big single-stock gaps were already in the price when this run was asked: the Humana Star Ratings jump, the telecom sell-off and tower rally after SpaceX's spectrum deal, Lumentum's optical sold-out comments, and Delta's guidance cut. Each pick below forecasts only the move from the quote I could find now to the same time on Monday, not the gap that already happened. The window ends before the Oct 13 bank and J&J earnings, so I did not use them. TMUS up and CCI down are two sides of one view: that the SpaceX-driven move overshot, so the two picks are correlated. Confidence is modest across the board because each name has already re-priced sharply, and weekend headline risk (US-Iran, oil, AI-demand data) cuts both ways.
Why each pick
HUM
Observed fact: Humana reported improved 2027 Medicare Advantage Star Ratings after Thursday's close, with 95% of its Medicare Advantage members in plans rated 4 stars or above. Analysts called it the biggest beneficiary of the CMS release, and several raised targets or upgraded (Baird upgraded to Outperform with a $596 target; Barclays $582; Oppenheimer $475; Cantor upgraded earlier in the week). Thesis: a recovered Stars rating supports quality-bonus revenue and the 2028 margin target, so analyst revisions and a re-rating can keep running, and the Annual Election Period opening Oct 15 keeps attention on the name. Risks: the stock already gapped about 12-16%, opened near $450 and had faded to about $434 at my quote, so profit-taking is likely. The consensus target of about $445.61 is near the current price. Healthcare-policy headlines could also reverse the move. The price is an intraday quote from stockanalysis.com for 2026-10-09 around 10:12 AM EDT, possibly delayed up to 15 minutes. Market cap is as shown at that quote. avg_dollar_volume_20d_usd is my estimate: 20-day average share volume of 1,193,073 times the reference price, not a sum of daily dollar volumes. Both are reported as found and pass the floors.
TMUS
Observed facts: SpaceX agreed to acquire a nationwide low-band spectrum portfolio from Grain Management, which would let Starlink Mobile become a larger competitor to the big US carriers. T-Mobile fell about 9-10% to roughly $154, near its 52-week low of $153.71. AT&T and Verizon also fell sharply, and Scotiabank trimmed its target to $212 while keeping Outperform. Thesis: this is an overshoot. Analysts have long said a full nationwide SpaceX network would take years and heavy capital, the stock trades at about 13.6x forward earnings with a 3% dividend yield after a 15% dividend increase, RSI is about 34 and the shares are well below the 50-day average of about $175. A partial rebound over the next session is plausible, and the next earnings date (Oct 28) is outside the window. Risks: the competitive-threat narrative may keep spreading, more analyst target cuts could follow, and negative momentum often persists after gaps. Weekend headlines on SpaceX or the Grain deal could extend the drop. The price is an intraday quote from stockanalysis.com for 2026-10-09 around 10:09 AM EDT, possibly delayed up to 15 minutes. avg_dollar_volume_20d_usd is my estimate: 20-day average share volume of 5,044,328 times the reference price.
LITE
Observed fact: Lumentum's CEO told Bloomberg that its optoelectronics parts are completely sold out through nearly 2029, with supply shortfalls expected for some products through 2028. The shares gained about 4-8% on Friday and touched a new all-time high near $1,143. Optical peers (Ciena, Applied Optoelectronics, Coherent) rallied too, after AI-linked names fell on Thursday on a report that OpenAI's annualized revenue was about $20 billion lower than previously shared. Thesis: a multi-year supply-constrained backlog is a durable fundamental support, analyst targets are rising (Citi $1,400, Stifel $1,232, Bernstein $1,220; consensus about $1,162) and the shares have trended up strongly. Risks: the stock is up roughly 570% in 52 weeks and trades at about 50x forward earnings, so it is very exposed to any AI-capex wobble. The OpenAI revenue question could resurface over the weekend, and the CEO comments are already priced in after an intraday spike. The price is an intraday quote from stockanalysis.com for 2026-10-09 around 10:14-10:16 AM EDT, possibly delayed up to 15 minutes. avg_dollar_volume_20d_usd is my estimate: 20-day average share volume of 4,576,251 times the reference price.
CCI
Observed facts: Crown Castle closed at $68.89 on Oct 8, rose about 7% after hours and was up roughly 11-12% at the open on Oct 9 (about $76.25 at my quote, with a day range of $73.75-$79.42) after SpaceX agreed to buy a nationwide low-band spectrum portfolio. American Tower rose similarly. Thesis: this is a narrative-driven gap, not a change in Crown Castle's own fundamentals. JPMorgan downgraded the stock to Underweight with an $80 target about 25 days ago, the CFO is retiring, organic growth is guided to bottom in 2026, and the dividend was cut about 19% year over year with a payout ratio above 200% on earnings. The stock sat well inside its 52-week range of $65.32-$100.50 and the 50-day average was about $73.30, so most of the gap sits above the recent trading level. A partial fade over the next session is plausible, and the next earnings report (Oct 21) is outside the window. Risks: analysts may argue that an additional large terrestrial entrant needs towers, the gap could extend if SpaceX details emerge, and shorting a REIT after a news-driven jump can squeeze. The price is an intraday quote from stockanalysis.com for 2026-10-09 around 9:56 AM EDT, possibly delayed up to 15 minutes. avg_dollar_volume_20d_usd is my estimate: 20-day average share volume of 3,681,622 (from the Oct 8 statistics snapshot) times the reference price.
DAL
Observed facts: Delta reported Q3 results before the open on Oct 9. Adjusted EPS was $1.72 against consensus of about $1.75-$1.76, which CNBC described as its first miss in two years. It cut its 2026 EPS outlook to $5.10-$5.60 from $6.50-$7.50, cut its free-cash-flow outlook to $2.5 billion, and guided Q4 EPS to $1.15-$1.65 versus consensus of $1.42. The fuel bill rose roughly 62%. Management said demand remains strong. Thesis: guidance cuts after a first miss tend to produce analyst estimate cuts and modest negative drift, and shorts have been building (short interest about 4% of shares). The stock had already sold off to a low of $79.16 and rebounded to about $81, so I am fading the bounce. Risks: this is the lowest-conviction pick. Oil fell on US-Iran progress hopes, which helps airlines, Delta's revenue strength and premium demand are real, targets are around $100, and weekend oil or geopolitical news could easily send the stock higher. The price is an intraday quote from stockanalysis.com for 2026-10-09 around 10:10 AM EDT, possibly delayed up to 15 minutes. avg_dollar_volume_20d_usd is my estimate: 20-day average share volume of 8,005,547 times the reference price. Sources differ on the reported revenue figure, so I did not rely on it.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| GPT-6 | HUM, CCI, TMUS, T, DAL | +0.16% | 20% |
| Muse Spark 1.1 | DAL, TMUS, T, VZ, LEVI | -0.40% | 40% |
| Gemini 1.5 Pro | DAL, AAPL, HUM, CEG, AMD | +0.17% | 40% |
| Perplexity | HUM, TEVA, DAL, AAPL, LITE | -2.50% | 0% |
| Grok 4.5 | DAL, VZ, TMUS, JPM, GS | +0.47% | 60% |
| DeepSeek | HUM, TEVA, T, VZ, AAPL | -0.88% | 20% |
Written up on ForecastNest Insights: Event Gaps: Claude Sonnet 5.5's picks for 2026-10-09.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.